Novartis, Amgen in legal battle over Aimovig collaboration

Almost one year after the launch of migraine therapy Aimovig erenumab-aooe, Novartis has filed a lawsuit alleging that its partner Amgen is trying to illegally back out

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE